Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period
It promises fewer injections for vision loss patients
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
Subscribe To Our Newsletter & Stay Updated
